- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Binge eating scale.
Displaying page 1 of 1.
EudraCT Number: 2021-000472-11 | Sponsor Protocol Number: P20-08/BP1.4979 | Start Date*: 2021-11-30 | |||||||||||
Sponsor Name:BIOPROJET PHARMA | |||||||||||||
Full Title: A double-blind, placebo-controlled pilot trial of BP1.4979 for the treatment of binge eating disorder | |||||||||||||
Medical condition: Binge eating disorder (BED) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004457-88 | Sponsor Protocol Number: SPD489-346 | Start Date*: 2014-03-05 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eati... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003310-14 | Sponsor Protocol Number: SPD489-344 | Start Date*: 2013-06-18 |
Sponsor Name:Shire Development LLC | ||
Full Title: The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003309-91 | Sponsor Protocol Number: SPD489-343 | Start Date*: 2013-03-20 |
Sponsor Name:Shire Development, LLC | ||
Full Title: The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001490-16 | Sponsor Protocol Number: SCÄ01 | Start Date*: 2017-11-13 |
Sponsor Name:Stockholms läns landsting | ||
Full Title: Lisdexamphetamine treatment of Bulimia Nervosa with and without probable simultaneous Attention Deficit Hyperactivity Disorder (ADHD). A randomized , open, fase II-study with cross-over design. | ||
Medical condition: Bulimia Nervosa with and without simultaneous Attention Deficit Hyperactivity Disorder. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003313-34 | Sponsor Protocol Number: SPD489-345 | Start Date*: 2013-03-28 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-016663-11 | Sponsor Protocol Number: ORA111850 | Start Date*: 2010-08-27 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 35-Day, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate the Effects of GSK1521498 on Body Weight and Composition, Eating Behaviour... | |||||||||||||
Medical condition: GSK1521498 is a novel opioid receptor inverse agonist that is being developed for the treatment of obesity. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002712-51 | Sponsor Protocol Number: 2020 | Start Date*: 2021-03-05 | |||||||||||
Sponsor Name:Kirsi Pietiläinen | |||||||||||||
Full Title: Semaglutide as an adjunct to dieting in the treatment of type 2 diabetes – effects on glucose metabolism, prevention of weight regain and peripheral tissue metabolic activation | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001049-24 | Sponsor Protocol Number: NN8022-1839 | Start Date*: 2008-12-02 | ||||||||||||||||
Sponsor Name:Novo Nordisk A/S | ||||||||||||||||||
Full Title: Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multina... | ||||||||||||||||||
Medical condition: Obesity and overweight Pre-diabetes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) FI (Completed) ES (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003177-58 | Sponsor Protocol Number: SPIOMET4HEALTH | Start Date*: 2022-05-12 | |||||||||||
Sponsor Name:Fundació Sant Joan de Déu (FSJD) | |||||||||||||
Full Title: A Phase II, randomised, multi-centric, multi-national clinical trial to evaluate the efficacy, tolerability, and safety of a fixed dose combination of Spironolactone, Pioglitazone & Metformin (SPIO... | |||||||||||||
Medical condition: Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
